About Event

Who Attended?

Companies Attending - 3rd Cell Therapy Potency Assay Summit
Companies Attending - 3rd Cell Therapy Potency Assay Summit
Companies Attending - 3rd Cell Therapy Potency Assay Summit
Companies Attending - 3rd Cell Therapy Potency Assay Summit
Companies Attending - 3rd Cell Therapy Potency Assay Summit
Companies Attending - 3rd Cell Therapy Potency Assay Summit

The 3rd Cell Therapy Potency Assay Summit was an unparalleled event for the cell therapy field, serving as a pivotal hub that brought together leading analytical, quality control (QC) and regulatory experts from across the world. Our mission is clear: to define, characterize, and measure the potency of diverse cell types, perfectly tailored for both QC and commercial environments.

In 2024, the summit went above and beyond – offering 6 interactive discussion-based workshops as well as two main conference days with different tracks highlighting a vast array of cell types including T cells, NK cells, TILs, stem cells, cardiomyocytes, and more.

From the earliest stages of characterization to the final steps of preparing for release and commercialization, our diverse program provided a comprehensive and unparalleled journey through end-to-end potency assay considerations. With a focus on practical insights, this summit equipped you with the knowledge and expertise to ensure you’re prepared to excel in your role, which ultimately will bring better therapies to patients faster.

''The interactions with the participants were outstanding, there was so much willingness to share and learn from each other to accelerate progress towards the same goal – get our therapies to the patients. That was very helpful and enjoyable” 

Associate Director, Cellectis 

What Hot Topics were Discussed?

Learn about potency assay development from a variety of different perspectives beyond T cells including NK cells, macrophages, cardiomyocytes and more with Century Therapeutics, IN8Bio & SIRPant Immunotherapeutics

Understand the regulatory basis for the necessity of cell therapy potency assays with Health Canada

Develop a matrix-based approach to potency assay development to elucidate the complex mechanism of action with BioNTech US, BlueRock Therapeutics & Cabaletta Bio

Review considerations for phase appropriate potency assay design and development, supporting product comparability needs with Cartesian Therapeutics & Affini-T Therapeutics

Explore quality control requirements and strategies to redefine and validate potency assays with Aisar Biotechnology, BMS & Fate Therapeutics